

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 180021 WO03	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/EP2019/070628	International filing date (<i>day/month/year</i>) 31 July 2019 (31-07-2019)	(Earliest) Priority Date (<i>day/month/year</i>) 1 August 2018 (01-08-2018)
Applicant NOVO NORDISK A/S		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 7 sheets.

☒

It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of:

☒

the international application in the language in which it was filed

☐

a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

b. ☐

This international search report has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43.6**bis**(a)).

c. ☒

With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐

Certain claims were found unsearchable (See Box No. II)

3. ☐

Unity of invention is lacking (see Box No III)

4. With regard to the **title**,

☒

the text is approved as submitted by the applicant

☐

the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒

the text is approved as submitted by the applicant

☐

the text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority

6. With regard to the **drawings**,

a. the figure of the **drawings** to be published with the abstract is Figure No. _____

☐

as suggested by the applicant

☐

as selected by this Authority, because the applicant failed to suggest a figure

☐

as selected by this Authority, because this figure better characterizes the invention

b. ☒

none of the figures is to be published with the abstract

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2019/070628

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
- a. ☒ forming part of the international application as filed:
- ☒ in the form of an Annex C/ST.25 text file.
- ☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
- ☐ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
- ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2019/070628

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/36 C07K16/40 C07K16/46 A61P7/04
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 2 644 698 A1 (CHUGAI PHARMACEUTICAL CO LTD [JP]) 2 October 2013 (2013-10-02) cited in the application paragraphs [0008], [0096], [0097] -----	1-11, 14-17
X	ZENJIRO SAMPEI ET AL: "Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity", PLOS ONE, vol. 8, no. 2, 28 February 2013 (2013-02-28), page e57479, XP055553036, DOI: 10.1371/journal.pone.0057479 cited in the application the whole document ----- -/--	2-11,14



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 September 2019

Date of mailing of the international search report

01/10/2019

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Turri, Matteo

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2019/070628

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TAKEHISA KITAZAWA ET AL: "A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model", NATURE MEDICINE, vol. 18, no. 10, 30 September 2012 (2012-09-30), pages 1570-1574, XP055246561, New York ISSN: 1078-8956, DOI: 10.1038/nm.2942 the whole document	2-11,14
A	----- Naoki Uchida ET AL: "Plenary Paper CLINICAL TRIALS AND OBSERVATIONS A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects", 1 December 2015 (2015-12-01), XP055468638, DOI: 10.1182/blood-2015-06-650226 Retrieved from the Internet: URL: http://www.bloodjournal.org/content/bloodjournal/127/13/1633.full.pdf?sso-checked=true [retrieved on 2018-04-19] the whole document	1-18
A	----- EP 1 660 536 A2 (BAXTER INT [US]; BAXTER HEALTHCARE SA [CH]) 31 May 2006 (2006-05-31)	1-18
A	----- F. SCHEIFLINGER ET AL: "Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 6, no. 2, 1 February 2008 (2008-02-01), pages 315-322, XP055553780, GB ISSN: 1538-7933, DOI: 10.1111/j.1538-7836.2007.02868.x	1-18
A	----- RANDOLF J. KERSCHBAUMER ET AL: "An Antibody Specific for Coagulation Factor IX Enhances the Activity of the Intrinsic Factor X-activating Complex", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 39, 24 September 2004 (2004-09-24), pages 40445-40450, XP055553782, US ISSN: 0021-9258, DOI: 10.1074/jbc.M405966200 ----- -/--	1-18

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2019/070628

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TAKEHISA KITAZAWA ET AL: "Factor Villa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens", THROMBOSIS AND HAEMOSTASIS, vol. 117, no. 07, 8 July 2017 (2017-07-08) , pages 1348-1357, XP055553028, DE ISSN: 0340-6245, DOI: 10.1160/TH17-01-0030 -----	1-18
A	WO 2018/098363 A2 (BIOVERATIV THERAPEUTICS INC [US]) 31 May 2018 (2018-05-31) -----	1-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2019/070628

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
EP 2644698	A1	02-10-2013	AU	2011330184	A1	09-05-2013
			AU	2016203564	A1	16-06-2016
			CA	2817964	A1	24-05-2012
			CN	103298937	A	11-09-2013
			CN	105859889	A	17-08-2016
			DK	2644698	T3	22-01-2018
			EP	2644698	A1	02-10-2013
			EP	3318633	A1	09-05-2018
			ES	2660151	T3	21-03-2018
			HK	1223379	A1	28-07-2017
			HR	P20180421	T1	20-04-2018
			HU	E038305	T2	29-10-2018
			HU	S1800029	I1	30-07-2018
			JP	5246905	B1	24-07-2013
			JP	5246906	B1	24-07-2013
			JP	6013915	B2	25-10-2016
			JP	2013143942	A	25-07-2013
			JP	2013150604	A	08-08-2013
			JP	2017046697	A	09-03-2017
			JP	2019129826	A	08-08-2019
			JP	WO2012067176	A1	12-05-2014
			KR	20130102113	A	16-09-2013
			KR	20130102640	A	17-09-2013
			KR	20130108407	A	02-10-2013
			KR	20190033644	A	29-03-2019
			LT	2644698	T	26-02-2018
			LT	PA2018507	I1	25-06-2018
			LU	C00076	I2	30-07-2018
			MX	355060	B	03-04-2018
			MY	166429	A	26-06-2018
			NO	2644698	T3	02-06-2018
			PH	12016502073	A1	29-01-2018
			PL	2644698	T3	29-06-2018
			PT	2644698	T	31-01-2018
			RU	2013118448	A	27-10-2014
			SI	2644698	T1	31-05-2018
			TR	201802772	T4	21-03-2018
			TW	201243049	A	01-11-2012
			TW	201414835	A	16-04-2014
			TW	201414836	A	16-04-2014
			TW	201631153	A	01-09-2016
			US	2013330345	A1	12-12-2013
			US	2014037632	A1	06-02-2014
			US	2014370018	A1	18-12-2014
			US	2016222129	A1	04-08-2016
			US	2017022293	A1	26-01-2017
			WO	2012067176	A1	24-05-2012

EP 1660536	A2	31-05-2006	AT	419277	T	15-01-2009
			AU	2004271706	A1	24-03-2005
			CA	2538895	A1	24-03-2005
			EP	1660536	A2	31-05-2006
			ES	2320665	T3	27-05-2009
			JP	4887148	B2	29-02-2012
			JP	2007504812	A	08-03-2007
			US	2005058640	A1	17-03-2005
WO	2005025615	A2	24-03-2005			

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2019/070628

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2018098363 A2	31-05-2018	AU 2017363309 A1	11-07-2019
		CA 3044574 A1	31-05-2018
		CO 2019006500 A2	28-06-2019
		EP 3545002 A2	02-10-2019
		KR 20190080949 A	08-07-2019
		TW 201819417 A	01-06-2018
		WO 2018098363 A2	31-05-2018
